“US President Donald Trump’s policy to end “freeloading” and force trading partners to increase prices they pay for US pharmaceutical exports is a direct threat to Australia’s policy of ensuring affordable medicines through our Pharmaceutical Benefit Sche
The US government — backed strongly by the pharmaceutical lobby — is expected to step up pressure on several governments, including India, to enforce and protect intellectual property (IP) of pharmaceutical corporations